Thomson Reuters and Clifford Chance have jointly launched a solution to help banks tackle regulatory obligations relating to margin rules for uncleared over-the-counter (OTC) derivatives.

The solution involves TR’s contract automation software, Contract Express, and abstraction technology built specifically for OTC documentation. 

The platform is expected to rapidly generate documentation to clients’ specifications, extract key terms from existing documentation and enable advanced analytics of the clients’ agreements. 



Related Articles

Deals

CC, Paul Hastings lead on CR Beverages’ HK IPO

by Charlie Wu 吴卓言 |

Clifford Chance and Jingtian & Gongcheng are advising China Resources Beverages, the beverage division of the state-owned China Resources Enterprise, on its upcoming Hong Kong IPO, which is expected to raise up to $1 billion. Paul Hastings and Zhong Lun Law Firm are acting for the joint sponsors.

Deals

Haiwen, CC advise on China TCM's $2 bln take-private deal

by Hu Yangxiaoxiao 胡阳潇潇 |

Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.

Deals

CC, Davis Polk act on ChaPanda’s $330 mln Hong Kong IPO

by Charlie Wu 吴卓言 |

Davis Polk & Wardwell and Jingtian & Gongcheng have advised Sichuan Baicha Baidao, a Chinese low-priced tea chain also known as ChaPanda, on its $330 million IPO on the Hong Kong Stock Exchange, with Clifford Chance and King & Wood Mallesons acting for the sponsor CICC and underwriters.